ClinicalTrials.gg
CompletedNCT03483103Updated Dec 20, 2023Results posted

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

A Phase 2 interventional study of lisocabtagene maraleucel in Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin and Lymphoma, B-Cell, sponsored by Juno Therapeutics, a Subsidiary of Celgene. Completed at 59 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-20.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: Lymphoma, Non-HodgkinReclassifiedWhy we changed it
Registry
Lymphoma, Non-Hodgkin — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. The study's listed conditions name Lymphoma, Large B-Cell, Diffuse, a narrower term within Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Juno Therapeutics, a Subsidiary of Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb — none open to participants now, 1 under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · Bristol-Myers Squibb.

Enrollment
12th of 19
74 · median 104
Started
2018
with 3 others
Phase 2
6 of 22
none open now
Registered
16th of 22
by date

Among the 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb, this one is the 12th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2018, is one of 6 in phase 2, and was the 16th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

None of the 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb as a file.
02

Study summary

This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status, quality of life, and survival.

03

Conditions studied

  • Lymphoma, Non-Hodgkin
  • Lymphoma, Nonhodgkin
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse

Browse trials for

Keywords

  • JCAR017
  • lisocabtagene maraleucel
  • NHL
  • chimeric antigen receptor
  • CAR
  • CAR T cell
  • autologous T cell therapy
  • immunotherapy
  • cell therapy
  • liso-cel
04

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's enrollment of 74 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

Juno Therapeutics, a Subsidiary of Celgene is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.

First submitted before Juno Therapeutics, Inc. became part of Bristol-Myers Squibb.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmation of aggressive B-cell non-Hodgkin lymphoma of the following histology at relapse: diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS; de novo or transformed follicular lymphoma [tFL]), high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (double/triple hit lymphoma [DHL/THL]), and follicular lymphoma Grade 3B per WHO 2016 classification
  • Previous treatment must include treatment with a single line of chemoimmunotherapy containing an anthracycline and a CD20-targeted agent
  • Subjects must be deemed ineligible for both high-dose chemotherapy and hematopoietic stem cell transplant (based on age, performance status and/or comorbidities) while also having adequate organ function for CAR T cell treatment.
  • Positron emission tomography (PET)-positive disease
  • Histological confirmation of diagnosis at last relapse. Enough tumor material must be available for central confirmation of diagnosis, otherwise a new tumor is mandated.
  • performance status of 0, or 1, or 2
  • Adequate vascular access for leukapheresis procedure (either peripheral line or surgically-placed line)
  • Subjects must agree to use appropriate
  • Subjects must agree to not donate blood, organs, semen, and egg cells for usage in other individuals for at least 1 year following lymphodepleting chemotherapy

Exclusion criteria

Exclusion Criteria:

  • Subjects with central nervous system (CNS)-only involvement by (note: subjects with secondary CNS involvement are allowed on study)
  • History of another primary malignancy that has not been in remission for at least 2 years.
  • Previous treatment with CD19-targeted therapy, with the exception of prior lisocabtagene maraleucel treatment in this protocol for subjects receiving retreatment
  • Active or infection at the time of screening
  • History of or active (HIV) infection at the time of screening
  • Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or lisocabtagene maraleucel administration
  • History of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the , cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other cardiac disease
  • History or presence of clinically relevant CNS pathology
  • Pregnant or nursing women
  • Subject does not meet protocol-specified for prior treatments
  • Prior hematopoietic stem cell transplant
  • Progressive vascular tumor invasion, thrombosis, or embolism
  • Venous thrombosis or embolism not managed on stable regimen of anticoagulation
  • Uncontrolled medical, psychological, familial, sociological, or geographical conditions
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Treatment

    Lisocabtagene maraleucel at a dose of 100×10\^6 CAR+ T cells (50×10\^6 CD8+ CAR+ T cells and 50×10\^6 CD4+ CAR+ T cells), will be given IV in a single-dose schedule on Day 1 (between 2 and 7 days following the completion of lymphodepleting chemotherapy).

    Biological: lisocabtagene maraleucel

Interventions

  • lisocabtagene maraleucel will be administered as a single dose intravenous (IV) injection

    Also known as: JCAR017, liso-cel

07

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Overall response rate is the percent of participants with a best overall response (BOR) of either complete response (CR) or partial reasons (PR) based on the Independent Review Committee (IRC) assessment recorded from the time of JCAR017 treatment until disease progression, end of study, the start of another anticancer therapy or JCAR017 retreatment. CR = Score 1, 2, or 3 with or without a residual mass on the positron emission tomography 5-point scale (PET 5PS). A score of 3 in many patients indicates a good prognosis with standard treatment. PR = Score 4 or 5b with reduced uptake compared with baseline and residual mass(es) of any size. PET 5PS = 1- no uptake above background; 2- uptake ≤ mediastinum; 3- uptake \> mediastinum but ≤ liver; 4- uptake moderately \> liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.

    Time frame: From first dose to disease progression, end of study, the start of another anticancer therapy, or hematopoietic stem cell transplantation (up to approximately 24 months)

Secondary outcomes

  1. Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs)

    A TEAE was defined as an adverse event that started any time from initiation of product administration through and including 90 days following product administration. AEs that occurred after the initiation of subsequent anticancer therapy or product retreatment were not considered as product TEAE. AEs are graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (Version 4.03) (NCI CTCAE) guidelines where Grade 3= Severe, Grade 4= Life-threatening, and 5 = Death.

    Time frame: From first dose to 90 days following first dose (up to approximately 90 days)

  2. Change From Baseline of Hematology Laboratory Results: Hemoglobin

    Change from baseline in Hematology laboratory analysis. Includes Hemoglobin. Baseline is the last observation collected prior to or on the date of product infusion.

    Time frame: Baseline and Day 29

  3. Change From Baseline of Hematology Laboratory Results: Leukocytes, Lymphocytes, Neutrophils, Platelets

    Change from baseline in Hematology laboratory analysis. Includes Leukocytes, Lymphocytes, Neutrophils, and Platelets. Baseline is the last observation collected prior to or on the date of product infusion.

    Time frame: Baseline and Day 29

  4. Change From Baseline of Chemistry Laboratory Results: Albumin

    Change from baseline in Chemistry laboratory analysis. Includes Albumin. Baseline is the last observation collected prior to or on the date of product infusion.

    Time frame: Baseline and Day 29

  5. Change From Baseline of Chemistry Laboratory Results: Alanine Aminotransferase, Aspartate Aminotransferase, Lactate Dehydrogenase

    Change from baseline in Chemistry laboratory analysis. Includes Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase. Baseline is the last observation collected prior to or on the date of product infusion.

    Time frame: Baseline and Day 29

  6. Change From Baseline of Chemistry Laboratory Results: Bilirubin, Creatinine, Direct Bilirubin, Urate

    Change from baseline in Chemistry laboratory analysis. Includes Bilirubin, Creatinine, Direct Bilirubin, and Urate. Baseline is the last observation collected prior to or on the date of product infusion.

    Time frame: Baseline and Day 29

  7. Change From Baseline of Chemistry Laboratory Results: Calcium Corrected, Magnesium, Phosphate, Potassium, Sodium

    Change from baseline in Chemistry laboratory analysis. Includes Calcium Corrected, Magnesium, Phosphate, Potassium, and Sodium. Baseline is the last observation collected prior to or on the date of product infusion.

    Time frame: Baseline and Day 29

  8. Complete Response (CR) Rate

    Complete response rate (CRR) was defined as the percent of participants with a best overall response (BOR) of complete response (CR) based on the Independent Review Committee (IRC) assessment recorded from the time of JCAR017 treatment until disease progression, end of study, the start of another anticancer therapy or JCAR017 retreatment. CR = Score 1, 2, or 3 with or without a residual mass on the positron emission tomography 5-point scale (PET 5PS). A score of 3 in many patients indicates a good prognosis with standard treatment. PET 5PS = 1- no uptake above background; 2- uptake ≤ mediastinum; 3- uptake \> mediastinum but ≤ liver; 4- uptake moderately \> liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.

    Time frame: From first dose to disease progression, end of study, the start of another anticancer therapy, or hematopoietic stem cell transplant (up to approximately 24 months)

  9. Duration of Response (DOR)

    Duration of response (DOR) is defined as the time from first complete response(CR) or partial response (PR) to progressive disease (PD) or death, whichever occurred first. CR = Score 1, 2, or 3 on the positron emission tomography 5-point scale (PET 5PS). A score of 3 indicates a good prognosis with standard treatment. PR = Score 4 or 5b with reduced uptake compared with baseline and residual mass(es) of any size. PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1-no uptake above background; 2-uptake ≤ mediastinum; 3-uptake \> mediastinum but ≤ liver; 4-uptake moderately \> liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.

    Time frame: From first dose to up to approximately 24 months

  10. Duration of Response (DOR) in Participants With Complete Response (CR)

    DOR for participants with a best overall response of CR was defined as the time from documentation of first response (or CR) to progressive disease (PD) or death, whichever occurred first. The first documentation of CR/PR is the latest of all dates of required measurements to establish the response. The progression date is the earliest date of all assessments that led to a response assessment of PD. CR = Score 1, 2, or 3 on the positron emission tomography 5-point scale (PET 5PS). A score of 3 indicates a good prognosis with standard treatment. PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1-no uptake above background; 2-uptake ≤ mediastinum; 3-uptake \> mediastinum but ≤ liver; 4-uptake moderately \> liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.

    Time frame: From first dose to up to approximately 24 months

  11. Progression-Free Survival (PFS)

    PFS is defined as the time from JCAR017 infusion to progressive disease (PD) or death. Kaplan-Meier (KM) methodology will be used to analyze PFS. PD = Score 4 or 5b on the positron emission tomography 5-point scale (PET 5PS) with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1- no uptake above background; 2- uptake ≤ mediastinum; 3- uptake \> mediastinum but ≤ liver; 4- uptake moderately \> liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.

    Time frame: From first dose to progressive disease (PD) or death (up to approximately 24 months)

  12. Event-Free Survival (EFS)

    EFS is defined as the time from JCAR017 infusion to the earliest of the following events: death from any cause, progressive disease (PD), or starting a new anticancer therapy. Kaplan-Meier (KM) methodology will be used to analyze EFS. PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1-no uptake above background; 2-uptake ≤ mediastinum; 3-uptake \> mediastinum but ≤ liver; 4-uptake moderately \> liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.

    Time frame: From first dose to death from any cause, progressive disease (PD), or starting a new anticancer therapy (up to approximately 24 months)

  13. Overall Survival (OS)

    OS is defined as the time from JCAR017 infusion to the date of death. Kaplan-Meier (KM) methodology will be used to analyze OS.

    Time frame: From first dose to date of death (up to approximately 24 months)

  14. PK Parameters of JCAR017 in Blood as Assessed by qPCR: Cmax

    Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR). Cmax = Maximum observed blood concentration.

    Time frame: From first dose to up to 24 months

  15. PK Parameters of JCAR017 in Blood as Assessed by qPCR: Tmax

    Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR). Tmax = Time of maximum observed blood concentration.

    Time frame: From first dose to up to 24 months

  16. PK Parameters of JCAR017 in Blood as Assessed by qPCR: AUC (0-28)

    Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR). AUC (0-28) = Area under the curve for concentration.

    Time frame: From first dose to up to 24 months

  17. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Fatigue Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

    Time frame: Baseline and Day 29

  18. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Physical Functioning Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.

    Time frame: Baseline and Day 29

  19. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Cognitive Functioning Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.

    Time frame: Baseline and Day 29

  20. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Global Health/QoL Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.

    Time frame: Baseline and Day 29

  21. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Role Functioning Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.

    Time frame: Baseline and Day 29

  22. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Emotional Functioning Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.

    Time frame: Baseline and Day 29

  23. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Social Functioning Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.

    Time frame: Baseline and Day 29

  24. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Pain Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

    Time frame: Baseline and Day 29

  25. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Nausea/Vomiting Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

    Time frame: Baseline and Day 29

  26. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Constipation Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

    Time frame: Baseline and Day 29

  27. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Diarrhea Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

    Time frame: Baseline and Day 29

  28. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Insomnia Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

    Time frame: Baseline and Day 29

  29. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Dyspnea Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

    Time frame: Baseline and Day 29

  30. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Appetite Loss Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

    Time frame: Baseline and Day 29

  31. Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Financial Difficulties Subscale

    * Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.

    Time frame: Baseline and Day 29

  32. Health-Related Quality of Life (HRQoL) Assessed by the FACT-Lym Subscale

    The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) consists of the FACT-General scale and a 15-item lymphoma-specific additional concerns subscale (LYM). This scale addresses symptoms and functional limitations that are important to lymphoma patients. The LYM items are scored on a 0 ("Not at all") to 4 ("Very much") response scale. Items are aggregated to a single score on a 0-60 scale.

    Time frame: Baseline and Day 29

  33. Health-Related Quality of Life (HRQoL) Assessed by the EuroQol Instrument EQ-5D-5L

    The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-5L health states ranged from -.594 for the worst (55555) to 1 for the best (11111) for UK value set with an optimal health state is assigned a score of 1.00, death is assigned a score of 0.00 and negative values representing values as worse than dead. A change of .08 is considered to be a clinically meaningful change in health utility.

    Time frame: Baseline and Day 29

  34. Numbers of Intensive Care Unit (ICU) Inpatient Days

    The numbers of ICU inpatient days.

    Time frame: From first dose after JCAR017 infusion to up to approximately 24 months

  35. Numbers of Non-intensive Care Unit (ICU) Inpatient Days

    Number of non-ICU inpatient days.

    Time frame: From first dose after JCAR017 infusion to up to approximately 24 months

  36. The Number of Participants That Were Hospitalized For Adverse Events, Prophylaxis, Other

    Length of hospitalization stay was reported for up to 24 months post liso-cel infusion. Reasons for hospitalization include adverse events, prophylaxis, and other. Adverse events were reported for up to 90 days post liso-cel infusion.

    Time frame: From first dose after JCAR017 infusion to up to approximately 24 months

08

Results

Posted Dec 29, 2022

Participant flow

Pre-Treatment Phase
Participant flow — Pre-Treatment Phase
MilestoneLisocabtagene Maraleucel (JCAR017)
Started74
Completed63
Not completed11
Withdrew: Other reasons1
Withdrew: No longer meets eligibility criteria4
Withdrew: Disease-related complications1
Withdrew: Death5
Treatment Phase
Participant flow — Treatment Phase
MilestoneLisocabtagene Maraleucel (JCAR017)
Started63
Received jcar01761
Received nonconforming product1
Did not receive either jar017 or nonconforming product1
Completed30
Not completed33
Withdrew: Withdrawal by subject7
Withdrew: Other reasons1
Withdrew: Death23
Withdrew: Did not receive either jar017 or nonconforming product1
Withdrew: Received nonconforming product1

Outcome measures

PrimaryOverall Response Rate (ORR)

Overall response rate is the percent of participants with a best overall response (BOR) of either complete response (CR) or partial reasons (PR) based on the Independent Review Committee (IRC) assessment recorded from the time of JCAR017 treatment until disease progression, end of study, the start of another anticancer therapy or JCAR017 retreatment. CR = Score 1, 2, or 3 with or without a residual mass on the positron emission tomography 5-point scale (PET 5PS). A score of 3 in many patients indicates a good prognosis with standard treatment. PR = Score 4 or 5b with reduced uptake compared with baseline and residual mass(es) of any size. PET 5PS = 1- no uptake above background; 2- uptake ≤ mediastinum; 3- uptake \> mediastinum but ≤ liver; 4- uptake moderately \> liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.

Time frame:
From first dose to disease progression, end of study, the start of another anticancer therapy, or hematopoietic stem cell transplantation (up to approximately 24 months)
Reported as:
Number · Percent of Participants
Overall Response Rate (ORR)
Percent of ParticipantsLisocabtagene Maraleucel (JCAR017)
Overall Response Rate (ORR)80.3 (68.2 to 89.4)
Statistical analysis
  • Lisocabtagene Maraleucel (JCAR017) · Exact binomial test · p = <.0001 (One sided P-value is calculated based on the null hypothesis ORR \<= 50.2%)
SecondaryNumber of Participants With Any Treatment-Emergent Adverse Events (TEAEs)

A TEAE was defined as an adverse event that started any time from initiation of product administration through and including 90 days following product administration. AEs that occurred after the initiation of subsequent anticancer therapy or product retreatment were not considered as product TEAE. AEs are graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (Version 4.03) (NCI CTCAE) guidelines where Grade 3= Severe, Grade 4= Life-threatening, and 5 = Death.

Time frame:
From first dose to 90 days following first dose (up to approximately 90 days)
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs)
ParticipantsLisocabtagene Maraleucel (JCAR017)
Participants with any TEAE59
Participants with any serious TEAEs20
Participants with any Grade ≥ 3 TEAEs48
Participants with any product-related TEAE48
SecondaryChange From Baseline of Hematology Laboratory Results: Hemoglobin

Change from baseline in Hematology laboratory analysis. Includes Hemoglobin. Baseline is the last observation collected prior to or on the date of product infusion.

Time frame:
Baseline and Day 29
Reported as:
Mean · g/L
Change From Baseline of Hematology Laboratory Results: Hemoglobin
g/LLisocabtagene Maraleucel (JCAR017)
Change From Baseline of Hematology Laboratory Results: Hemoglobin1.9 ± 10.05
SecondaryChange From Baseline of Hematology Laboratory Results: Leukocytes, Lymphocytes, Neutrophils, Platelets

Change from baseline in Hematology laboratory analysis. Includes Leukocytes, Lymphocytes, Neutrophils, and Platelets. Baseline is the last observation collected prior to or on the date of product infusion.

Time frame:
Baseline and Day 29
Reported as:
Mean · 10^9 cells/L
Change From Baseline of Hematology Laboratory Results: Leukocytes, Lymphocytes, Neutrophils, Platelets
10^9 cells/LLisocabtagene Maraleucel (JCAR017)
Leukocytes0.921 ± 3.8562
Lymphocytes0.537 ± 0.5953
Neutrophils-0.216 ± 3.4010
Platelets-61.6 ± 96.55
SecondaryChange From Baseline of Chemistry Laboratory Results: Albumin

Change from baseline in Chemistry laboratory analysis. Includes Albumin. Baseline is the last observation collected prior to or on the date of product infusion.

Time frame:
Baseline and Day 29
Reported as:
Mean · g/L
Change From Baseline of Chemistry Laboratory Results: Albumin
g/LLisocabtagene Maraleucel (JCAR017)
Change From Baseline of Chemistry Laboratory Results: Albumin3.05 ± 3.866
SecondaryChange From Baseline of Chemistry Laboratory Results: Alanine Aminotransferase, Aspartate Aminotransferase, Lactate Dehydrogenase

Change from baseline in Chemistry laboratory analysis. Includes Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase. Baseline is the last observation collected prior to or on the date of product infusion.

Time frame:
Baseline and Day 29
Reported as:
Mean · U/L
Change From Baseline of Chemistry Laboratory Results: Alanine Aminotransferase, Aspartate Aminotransferase, Lactate Dehydrogenase
U/LLisocabtagene Maraleucel (JCAR017)
Alanine Aminotransferase4.6 ± 16.42
Aspartate Aminotransferase-3.9 ± 21.22
Lactate Dehydrogenase-138.2 ± 339.82
SecondaryChange From Baseline of Chemistry Laboratory Results: Bilirubin, Creatinine, Direct Bilirubin, Urate

Change from baseline in Chemistry laboratory analysis. Includes Bilirubin, Creatinine, Direct Bilirubin, and Urate. Baseline is the last observation collected prior to or on the date of product infusion.

Time frame:
Baseline and Day 29
Reported as:
Mean · umol/L
Change From Baseline of Chemistry Laboratory Results: Bilirubin, Creatinine, Direct Bilirubin, Urate
umol/LLisocabtagene Maraleucel (JCAR017)
Bilirubin-0.1741 ± 6.36075
Creatinine5.8734 ± 21.32985
Direct Bilirubin0.0306 ± 2.35650
Urate5.7897 ± 93.90174
SecondaryChange From Baseline of Chemistry Laboratory Results: Calcium Corrected, Magnesium, Phosphate, Potassium, Sodium

Change from baseline in Chemistry laboratory analysis. Includes Calcium Corrected, Magnesium, Phosphate, Potassium, and Sodium. Baseline is the last observation collected prior to or on the date of product infusion.

Time frame:
Baseline and Day 29
Reported as:
Mean · mmol/L
Change From Baseline of Chemistry Laboratory Results: Calcium Corrected, Magnesium, Phosphate, Potassium, Sodium
mmol/LLisocabtagene Maraleucel (JCAR017)
Calcium Corrected-0.0261 ± 0.12183
Magnesium-0.0209 ± 0.09292
Phosphate0.0479 ± 0.22624
Potassium-0.05 ± 0.426
Sodium1.0 ± 3.37
SecondaryComplete Response (CR) Rate

Complete response rate (CRR) was defined as the percent of participants with a best overall response (BOR) of complete response (CR) based on the Independent Review Committee (IRC) assessment recorded from the time of JCAR017 treatment until disease progression, end of study, the start of another anticancer therapy or JCAR017 retreatment. CR = Score 1, 2, or 3 with or without a residual mass on the positron emission tomography 5-point scale (PET 5PS). A score of 3 in many patients indicates a good prognosis with standard treatment. PET 5PS = 1- no uptake above background; 2- uptake ≤ mediastinum; 3- uptake \> mediastinum but ≤ liver; 4- uptake moderately \> liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.

Time frame:
From first dose to disease progression, end of study, the start of another anticancer therapy, or hematopoietic stem cell transplant (up to approximately 24 months)
Reported as:
Number · Percent of Participants
Complete Response (CR) Rate
Percent of ParticipantsLisocabtagene Maraleucel (JCAR017)
Complete Response (CR) Rate54.1 (40.8 to 66.9)
SecondaryDuration of Response (DOR)

Duration of response (DOR) is defined as the time from first complete response(CR) or partial response (PR) to progressive disease (PD) or death, whichever occurred first. CR = Score 1, 2, or 3 on the positron emission tomography 5-point scale (PET 5PS). A score of 3 indicates a good prognosis with standard treatment. PR = Score 4 or 5b with reduced uptake compared with baseline and residual mass(es) of any size. PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1-no uptake above background; 2-uptake ≤ mediastinum; 3-uptake \> mediastinum but ≤ liver; 4-uptake moderately \> liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.

Time frame:
From first dose to up to approximately 24 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsLisocabtagene Maraleucel (JCAR017)
Duration of Response (DOR)23.26 (6.24 to NA)
SecondaryDuration of Response (DOR) in Participants With Complete Response (CR)

DOR for participants with a best overall response of CR was defined as the time from documentation of first response (or CR) to progressive disease (PD) or death, whichever occurred first. The first documentation of CR/PR is the latest of all dates of required measurements to establish the response. The progression date is the earliest date of all assessments that led to a response assessment of PD. CR = Score 1, 2, or 3 on the positron emission tomography 5-point scale (PET 5PS). A score of 3 indicates a good prognosis with standard treatment. PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1-no uptake above background; 2-uptake ≤ mediastinum; 3-uptake \> mediastinum but ≤ liver; 4-uptake moderately \> liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.

Time frame:
From first dose to up to approximately 24 months
Reported as:
Median · Months
Duration of Response (DOR) in Participants With Complete Response (CR)
MonthsLisocabtagene Maraleucel (JCAR017)
Duration of Response (DOR) in Participants With Complete Response (CR)NA (21.65 to NA)
SecondaryProgression-Free Survival (PFS)

PFS is defined as the time from JCAR017 infusion to progressive disease (PD) or death. Kaplan-Meier (KM) methodology will be used to analyze PFS. PD = Score 4 or 5b on the positron emission tomography 5-point scale (PET 5PS) with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1- no uptake above background; 2- uptake ≤ mediastinum; 3- uptake \> mediastinum but ≤ liver; 4- uptake moderately \> liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.

Time frame:
From first dose to progressive disease (PD) or death (up to approximately 24 months)
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsLisocabtagene Maraleucel (JCAR017)
Progression-Free Survival (PFS)9.03 (4.17 to NA)
SecondaryEvent-Free Survival (EFS)

EFS is defined as the time from JCAR017 infusion to the earliest of the following events: death from any cause, progressive disease (PD), or starting a new anticancer therapy. Kaplan-Meier (KM) methodology will be used to analyze EFS. PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1-no uptake above background; 2-uptake ≤ mediastinum; 3-uptake \> mediastinum but ≤ liver; 4-uptake moderately \> liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.

Time frame:
From first dose to death from any cause, progressive disease (PD), or starting a new anticancer therapy (up to approximately 24 months)
Reported as:
Median · Months
Event-Free Survival (EFS)
MonthsLisocabtagene Maraleucel (JCAR017)
Event-Free Survival (EFS)7.23 (3.22 to 24.28)
SecondaryOverall Survival (OS)

OS is defined as the time from JCAR017 infusion to the date of death. Kaplan-Meier (KM) methodology will be used to analyze OS.

Time frame:
From first dose to date of death (up to approximately 24 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsLisocabtagene Maraleucel (JCAR017)
Overall Survival (OS)NA (16.33 to NA)
SecondaryPK Parameters of JCAR017 in Blood as Assessed by qPCR: Cmax

Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR). Cmax = Maximum observed blood concentration.

Time frame:
From first dose to up to 24 months
Reported as:
Geometric mean · copies/μg
PK Parameters of JCAR017 in Blood as Assessed by qPCR: Cmax
copies/μgLisocabtagene Maraleucel (JCAR017)
PK Parameters of JCAR017 in Blood as Assessed by qPCR: Cmax22516.3 ± 237.4
SecondaryPK Parameters of JCAR017 in Blood as Assessed by qPCR: Tmax

Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR). Tmax = Time of maximum observed blood concentration.

Time frame:
From first dose to up to 24 months
Reported as:
Median · Day
PK Parameters of JCAR017 in Blood as Assessed by qPCR: Tmax
DayLisocabtagene Maraleucel (JCAR017)
PK Parameters of JCAR017 in Blood as Assessed by qPCR: Tmax10.0 (6 to 22)
SecondaryPK Parameters of JCAR017 in Blood as Assessed by qPCR: AUC (0-28)

Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR). AUC (0-28) = Area under the curve for concentration.

Time frame:
From first dose to up to 24 months
Reported as:
Geometric mean · day*copies/ug
PK Parameters of JCAR017 in Blood as Assessed by qPCR: AUC (0-28)
day*copies/ugLisocabtagene Maraleucel (JCAR017)
PK Parameters of JCAR017 in Blood as Assessed by qPCR: AUC (0-28)178631.0 ± 228.3
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Fatigue Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Fatigue Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline36.706 ± 27.6193
Day 2937.731 ± 19.9473
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Physical Functioning Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Physical Functioning Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline77.827 ± 24.2897
Day 2971.667 ± 23.8395
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Cognitive Functioning Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Cognitive Functioning Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline83.333 ± 17.4078
Day 2988.194 ± 14.9698
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Global Health/QoL Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Global Health/QoL Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline66.815 ± 25.5491
Day 2972.049 ± 18.7910
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Role Functioning Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Role Functioning Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline77.083 ± 30.4117
Day 2969.792 ± 28.0695
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Emotional Functioning Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Emotional Functioning Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline81.061 ± 17.1575
Day 2986.806 ± 13.4077
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Social Functioning Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Social Functioning Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline74.702 ± 26.3985
Day 2972.917 ± 25.8713
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Pain Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Pain Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline26.488 ± 29.2631
Day 2913.542 ± 22.4546
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Nausea/Vomiting Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Nausea/Vomiting Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline5.655 ± 10.6727
Day 296.250 ± 14.4338
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Constipation Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Constipation Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline11.905 ± 23.2931
Day 296.944 ± 13.6805
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Diarrhea Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Diarrhea Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline13.690 ± 21.8135
Day 2911.806 ± 21.1821
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Insomnia Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Insomnia Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline25.595 ± 27.7005
Day 2920.139 ± 27.2798
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Dyspnea Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Dyspnea Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline10.714 ± 21.1843
Day 2913.194 ± 17.8510
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Appetite Loss Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Appetite Loss Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline18.788 ± 29.9270
Day 2922.222 ± 28.6277
SecondaryMean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Financial Difficulties Subscale

* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Financial Difficulties Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline13.690 ± 22.7208
Day 2914.583 ± 21.6421
SecondaryHealth-Related Quality of Life (HRQoL) Assessed by the FACT-Lym Subscale

The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) consists of the FACT-General scale and a 15-item lymphoma-specific additional concerns subscale (LYM). This scale addresses symptoms and functional limitations that are important to lymphoma patients. The LYM items are scored on a 0 ("Not at all") to 4 ("Very much") response scale. Items are aggregated to a single score on a 0-60 scale.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Health-Related Quality of Life (HRQoL) Assessed by the FACT-Lym Subscale
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline44.22 ± 8.804
Day 2948.71 ± 6.447
SecondaryHealth-Related Quality of Life (HRQoL) Assessed by the EuroQol Instrument EQ-5D-5L

The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-5L health states ranged from -.594 for the worst (55555) to 1 for the best (11111) for UK value set with an optimal health state is assigned a score of 1.00, death is assigned a score of 0.00 and negative values representing values as worse than dead. A change of .08 is considered to be a clinically meaningful change in health utility.

Time frame:
Baseline and Day 29
Reported as:
Mean · Scores on a scale
Health-Related Quality of Life (HRQoL) Assessed by the EuroQol Instrument EQ-5D-5L
Scores on a scaleLisocabtagene Maraleucel (JCAR017)
Baseline0.7378 ± 0.23190
Day 290.7719 ± 0.20651
SecondaryNumbers of Intensive Care Unit (ICU) Inpatient Days

The numbers of ICU inpatient days.

Time frame:
From first dose after JCAR017 infusion to up to approximately 24 months
Reported as:
Median · Day
Numbers of Intensive Care Unit (ICU) Inpatient Days
DayLisocabtagene Maraleucel (JCAR017)
Numbers of Intensive Care Unit (ICU) Inpatient Days0.0 (0 to 30)
SecondaryNumbers of Non-intensive Care Unit (ICU) Inpatient Days

Number of non-ICU inpatient days.

Time frame:
From first dose after JCAR017 infusion to up to approximately 24 months
Reported as:
Median · Day
Numbers of Non-intensive Care Unit (ICU) Inpatient Days
DayLisocabtagene Maraleucel (JCAR017)
Numbers of Non-intensive Care Unit (ICU) Inpatient Days14.0 (3 to 34)
SecondaryThe Number of Participants That Were Hospitalized For Adverse Events, Prophylaxis, Other

Length of hospitalization stay was reported for up to 24 months post liso-cel infusion. Reasons for hospitalization include adverse events, prophylaxis, and other. Adverse events were reported for up to 90 days post liso-cel infusion.

Time frame:
From first dose after JCAR017 infusion to up to approximately 24 months
Reported as:
Number · Participants
The Number of Participants That Were Hospitalized For Adverse Events, Prophylaxis, Other
ParticipantsLisocabtagene Maraleucel (JCAR017)
Adverse Event2
Prophylaxis for CAR T-cell administration36
Other3

Adverse events

Collected over Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until study completion (up to approximately 52 months). SAEs and Other AEs were assessed from the first participant undergoing leukapheresis to 90 days following the first participant undergoing leukapheresis (up to approximately 90 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lisocabtagene Maraleucel (JCAR017)30/74 (40.5%)20/61 (32.8%)59/61 (96.7%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventLisocabtagene Maraleucel (JCAR017)
Cytokine release syndromeImmune system disorders8/61
Confusional statePsychiatric disorders3/61
Upper gastrointestinal haemorrhageGastrointestinal disorders2/61
Muscular weaknessMusculoskeletal and connective tissue disorders2/61
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/61
Febrile neutropeniaBlood and lymphatic system disorders1/61
Lower gastrointestinal haemorrhageGastrointestinal disorders1/61
Obstruction gastricGastrointestinal disorders1/61
BacteraemiaInfections and infestations1/61
COVID-19Infections and infestations1/61
Most frequent other events
Showing 10 of 39
Most frequent other events
EventLisocabtagene Maraleucel (JCAR017)
NeutropeniaBlood and lymphatic system disorders31/61
FatigueGeneral disorders24/61
AnaemiaBlood and lymphatic system disorders19/61
ThrombocytopeniaBlood and lymphatic system disorders18/61
NauseaGastrointestinal disorders15/61
Cytokine release syndromeImmune system disorders15/61
LeukopeniaBlood and lymphatic system disorders14/61
HypokalaemiaMetabolism and nutrition disorders11/61
HypomagnesaemiaMetabolism and nutrition disorders11/61
DiarrhoeaGastrointestinal disorders10/61

Baseline characteristics

74 participants were leukapheresed.

Age, Continuous
Age, Continuous(Years)Lisocabtagene Maraleucel (JCAR017)
Mean72.8 ± 6.57
Age, Customized
Age, Customized(Participants)Lisocabtagene Maraleucel (JCAR017)
< 65 years8
>= 65 to < 70 years7
>= 70 to < 75 years27
>= 75 years32
Sex: Female, Male
Sex: Female, Male(Participants)Lisocabtagene Maraleucel (JCAR017)
Female29
Male45
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lisocabtagene Maraleucel (JCAR017)
Hispanic or Latino1
Not Hispanic or Latino64
Unknown or Not Reported9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lisocabtagene Maraleucel (JCAR017)
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American2
White64
More than one race0
Unknown or Not Reported6
09

Study locations

59 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Local Institution - 0043
    Gilbert, Arizona 85234, United States
  • Scripps Clinic
    La Jolla, California 92037, United States
  • UNC School of Medicine
    Los Angeles, California 90095, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Sutter Hematology and Oncology
    Sacramento, California 95816, United States
  • Sutter Medical Center
    Sacramento, California 95816, United States
  • Stanford Cancer Genetics Clinic
    Stanford, California 94304, United States
  • Local Institution - 0092
    Stanford, California 94305, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Local Institution - 0019
    Atlanta, Georgia 30342, United States
  • The Blood and Marrow Transplant Group of Georgia
    Atlanta, Georgia 30342, United States
  • UNC School of Medicine
    Atlanta, Georgia 30342, United States
  • Local Institution - 0003
    Chicago, Illinois 60611, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Local Institution - 0016
    Chicago, Illinois 60637-1470, United States
  • University of Chicago
    Chicago, Illinois 60637-1470, United States
  • University of Chicago Comprehensive Cancer Center
    Chicago, Illinois 60637, United States
  • Local Institution - 0046
    Lexington, Kentucky 40536, United States
  • University of Kentucky/Markey Cancer Center
    Lexington, Kentucky 40536, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Local Institution - 0064
    Louisville, Kentucky 40241, United States
  • Norton Cancer Institute - Brownsboro
    Louisville, Kentucky 40241, United States
  • UNC School of Medicine
    Louisville, Kentucky 40241, United States
  • Johns Hopkins Oncology Center Bunting Blaustein Building
    Baltimore, Maryland 21231, United States
  • Local Institution - 0009
    Baltimore, Maryland 21231, United States
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21231, United States
  • Local Institution - 0052
    East Brunswick, New Jersey 08816, United States
  • Regional Cancer Care Associates
    East Brunswick, New Jersey 08816, United States
  • UNC School of Medicine
    East Brunswick, New Jersey 08816, United States
  • New York Oncology Hematology - Albany Cancer Center
    Albany, New York 12208, United States
  • New York Oncology Hematology P.C.
    Albany, New York 12208, United States
  • Local Institution - 0090
    Rochester, New York 14642, United States
  • University of Rochester Cancer Center
    Rochester, New York 14642, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0021
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0039
    Cincinnati, Ohio 45236, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45236, United States
  • Oncology Hematology Care
    Cincinnati, Ohio 45236, United States
  • Local Institution - 0051
    Portland, Oregon 97213, United States
  • Providence Cancer Center/Earle A. Chiles Res. Inst.
    Portland, Oregon 97213, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • Local Institution - 0029
    Pittsburgh, Pennsylvania 15232, United States
  • University of Pittsburgh Medical Center Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Greenville Health System - Cancer Institute - Faris Road
    Greenville, South Carolina 29605, United States
  • Greenville Health System
    Greenville, South Carolina 29615, United States
  • Local Institution - 0037
    Greenville, South Carolina 29615, United States
  • Local Institution - 0083
    Dallas, Texas 75390-7208, United States
  • UNC School of Medicine
    Dallas, Texas 75390, United States
  • Intermountain Healthcare - LDS Hospital Blood and Marrow Transplant
    Salt Lake City, Utah 84143, United States
  • Intermountain Healthcare - LDS Hospital
    Salt Lake City, Utah 84143, United States
  • Local Institution - 0074
    Salt Lake City, Utah 84143, United States
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
  • UNC School of Medicine
    Tacoma, Washington 98405, United States
  • Local Institution - 0055
    Milwaukee, Wisconsin 53226, United States
  • Medical College of Wisconsin, Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • UNC School of Medicine
    Milwaukee, Wisconsin 53226, United States
10

References and documents

Publications

  • Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022 Aug;23(8):1066-1077. doi: 10.1016/S1470-2045(22)00339-4. Epub 2022 Jul 12. PubMed 35839786 ↗
  • Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PubMed 34515338 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Sep 2021, 37 months.

Results were first posted in Dec 2022, 1 year 3 months after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 37 months is close to that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2018
First posted
Mar 30, 2018
StartActual
Jul 27, 2018
Primary completionActual
Sep 24, 2021
CompletionActual
Dec 1, 2022
Results first posted
Dec 29, 2022
Last update
Dec 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03483103
Responsible party
Sponsor
First posted
Mar 30, 2018
Start date
Jul 27, 2018
Primary completion
Sep 24, 2021
Completion
Dec 1, 2022
Results posted
Dec 29, 2022
Last update
Dec 20, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisocabtagene maraleucel

Start the discussion